Next Article in Journal
Major Ampullate Spider Silk with Indistinguishable Spidroin Dope Conformations Leads to Different Fiber Molecular Structures
Next Article in Special Issue
Hepatic Fasting-Induced PPARα Activity Does Not Depend on Essential Fatty Acids
Previous Article in Journal
MicroRNA-331-3p Suppresses Cervical Cancer Cell Proliferation and E6/E7 Expression by Targeting NRP2
Previous Article in Special Issue
Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2016, 17(8), 1347; doi:10.3390/ijms17081347

Sex-Based Selectivity of PPARγ Regulation in Th1, Th2, and Th17 Differentiation

1
Department of Life Science, College of Natural Sciences, Hanyang University, Seoul 04763, Korea
2
Research Institute for Natural Sciences, Hanyang University, Seoul 04763, Korea
3
Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
4
Center for Neuroscience Imaging Research (CNIR), Institute for Basic Science (IBS), Suwon 16419, Korea
*
Author to whom correspondence should be addressed.
Academic Editor: Béatrice Desvergne
Received: 13 June 2016 / Revised: 3 August 2016 / Accepted: 11 August 2016 / Published: 18 August 2016
View Full-Text   |   Download PDF [7219 KB, uploaded 18 August 2016]   |  

Abstract

Peroxisome proliferator-activated receptor gamma (PPARγ) has recently been recognized to regulate adaptive immunity through Th17 differentiation, Treg functions, and TFH responses. However, its role in adaptive immunity and autoimmune disease is still not clear, possibly due to sexual differences. Here, we investigated in vitro treatment study with the PPARγ agonist pioglitazone to compare Th1, Th2, and Th17 differentiation in male and female mouse splenic T cells. Pioglitazone treatment significantly inhibited various effector T cell differentiations including Th1, Th2, and Th17 cells from female naïve T cells, but it selectively reduced IL-17 production in male Th17 differentiation. Interestingly, pioglitazone and estradiol (E2) co-treatment of T cells in males inhibited differentiation of Th1, Th2, and Th17 cells, suggesting a mechanism for the greater sensitivity of PPARγ to ligand treatment in the regulation of effector T cell differentiation in females. Collectively, these results demonstrate that PPARγ selectively inhibits Th17 differentiation only in male T cells and modulates Th1, Th2, and Th17 differentiation in female T cells based on different level of estrogen exposure. Accordingly, PPARγ could be an important immune regulator of sexual differences in adaptive immunity. View Full-Text
Keywords: PPARγ; pioglitazone; effector T cells; estrogen; sex PPARγ; pioglitazone; effector T cells; estrogen; sex
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Park, H.-J.; Park, H.-S.; Lee, J.-U.; Bothwell, A.L.M.; Choi, J.-M. Sex-Based Selectivity of PPARγ Regulation in Th1, Th2, and Th17 Differentiation. Int. J. Mol. Sci. 2016, 17, 1347.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top